275 related articles for article (PubMed ID: 10027340)
21. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
Fleming RA; Milano G; Thyss A; Etienne MC; Renée N; Schneider M; Demard F
Cancer Res; 1992 May; 52(10):2899-902. PubMed ID: 1581906
[TBL] [Abstract][Full Text] [Related]
22. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients.
Van Kuilenburg AB; van Lenthe H; Blom MJ; Mul EP; Van Gennip AH
Br J Cancer; 1999 Feb; 79(3-4):620-6. PubMed ID: 10027339
[TBL] [Abstract][Full Text] [Related]
23. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A; Ezzeldin H; Fourie J; Diasio R
Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
[TBL] [Abstract][Full Text] [Related]
24. Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?
Saif MW; Seller S; Diasio RB
JOP; 2008 Mar; 9(2):226-9. PubMed ID: 18326935
[TBL] [Abstract][Full Text] [Related]
25. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
[TBL] [Abstract][Full Text] [Related]
26. 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
Cordier PY; Nau A; Ciccolini J; Oliver M; Mercier C; Lacarelle B; Peytel E
Cancer Chemother Pharmacol; 2011 Sep; 68(3):823-6. PubMed ID: 21553285
[TBL] [Abstract][Full Text] [Related]
27. [Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance].
Etienne MC; Milano G; Fleming RA; Thyss A; Renée N; Schneider M; Demard F
Bull Cancer; 1992; 79(12):1159-63. PubMed ID: 1304835
[TBL] [Abstract][Full Text] [Related]
28. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
[TBL] [Abstract][Full Text] [Related]
29. Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer.
Saeki H; Ito S; Futatsugi M; Kimura Y; Ohga T; Sugimachi K
Anticancer Res; 2002; 22(6B):3789-92. PubMed ID: 12552994
[TBL] [Abstract][Full Text] [Related]
30. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.
Magné N; Etienne-Grimaldi MC; Cals L; Renée N; Formento JL; Francoual M; Milano G
Br J Clin Pharmacol; 2007 Aug; 64(2):237-40. PubMed ID: 17335544
[TBL] [Abstract][Full Text] [Related]
31. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy.
Jiang W; Lu Z; He Y; Diasio RB
Clin Cancer Res; 1997 Mar; 3(3):395-9. PubMed ID: 9815697
[TBL] [Abstract][Full Text] [Related]
32. [Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency].
Beuzeboc P; Pierga JY; Lyonnet DS; Couturier J; Pouillart P
Bull Cancer; 1996 Apr; 83(4):324-7. PubMed ID: 8680084
[TBL] [Abstract][Full Text] [Related]
33. Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
Innocenti F; Ratain MJ
Clin Cancer Res; 2002 May; 8(5):1314; author reply 1315-6. PubMed ID: 12006555
[No Abstract] [Full Text] [Related]
34. [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].
Coriat R; Chaussade S
Therapie; 2007; 62(2):105-9. PubMed ID: 17582310
[TBL] [Abstract][Full Text] [Related]
35. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
Di Paolo A; Danesi R; Falcone A; Cionini L; Vannozzi F; Masi G; Allegrini G; Mini E; Bocci G; Conte PF; Del Tacca M
Ann Oncol; 2001 Sep; 12(9):1301-6. PubMed ID: 11697844
[TBL] [Abstract][Full Text] [Related]
36. Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin.
van Kuilenburg AB; Klumpen HJ; Westermann AM; Zoetekouw L; Van Lenthe H; Bakker PJ; Richel DJ; Guchelaar HJ
Eur J Cancer; 2007 Jan; 43(2):459-65. PubMed ID: 17097873
[TBL] [Abstract][Full Text] [Related]
37. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
38. [Population study of dihydropyrimidine dehydrogenase in cancer patients].
Etienne MC; Milano G; Renée N; Lagrange JL; Dassonville O; Thyss A; Schneider M; François E; Fleming R; Demard F
Bull Cancer; 1995 Sep; 82(9):705-10. PubMed ID: 8535028
[TBL] [Abstract][Full Text] [Related]
39. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question.
van Kuilenburg AB
Cancer Invest; 2006 Mar; 24(2):215-7. PubMed ID: 16537192
[TBL] [Abstract][Full Text] [Related]
40. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
